Today: 29 June 2026
Browse Category

NASDAQ:MRNA 8 October 2025 - 28 December 2025

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna shares fell 4.73% to $31.20 Friday, closing out a volatile holiday week with no major company news or FDA headlines in the past 48 hours. After-hours trading edged lower near $31.10. Barron’s and MarketBeat flagged the stock’s sharp move and heavy trading volume. Analyst commentary focused on technicals and sector positioning rather than new fundamentals.
28 December 2025
··
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna shares fell about 4.4% to $31.31 in early afternoon trading Tuesday, underperforming a steady broader market near record highs. Trading volume was light, typical for the post-holiday period. No single news event drove the decline, with analysts citing thin liquidity and ongoing uncertainty around U.S. vaccine policy and Moderna’s future pipeline.
26 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna shares fell 7.48% to $32.29 on Dec. 23 after a sharp rally earlier in the week. The drop followed news of up to $54.3 million in CEPI funding for its bird flu vaccine, with a Phase 3 trial set for early 2026. The stock’s volatility contrasted with broader market gains, as investors reacted to recent headlines and year-end trading dynamics.
24 December 2025
··
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna shares rose about 9% to $33.80 after the company secured up to $54.3 million from CEPI for a Phase 3 trial of its H5 bird flu vaccine. The funding follows a canceled U.S. government contract earlier this year. Meanwhile, U.S. regulators are reviewing possible COVID-19 vaccine safety issues, with conflicting reports on potential FDA warnings.
20 December 2025
·
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna shares closed at $27.70 on December 5, up 8.7% on volume over 16 million. The rally followed a major French study showing no increase in long-term mortality from mRNA COVID vaccines and a new $1.5 billion credit facility. The stock is still down more than 50% over the past year despite recent gains. Year-to-date performance remains negative at –38.7%.
6 December 2025
··
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna shares dropped 7% on December 1 after news that the FDA may tighten vaccine approval standards, following an internal memo linking COVID-19 vaccines to pediatric deaths. The stock rebounded to close at $27.70 on December 5, up 8.7% after a large French study reaffirmed the safety of its vaccine. Moderna’s market cap now stands at $10.8 billion, far below its pandemic peak.
6 December 2025
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna closed at $23.72 on Friday, near its 52-week low and down 38% over the past year. The company is now the most shorted stock in the S&P 500, with short interest near 18% as COVID vaccine sales collapse. Moderna has announced a new three-year strategy, $1.5 billion in new debt, and pipeline cuts while focusing on mRNA drugs for cancer and respiratory disease.
23 November 2025
·
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action

Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action

Moderna shareholders are voting today on a one-time stock option exchange for non-executive employees, which could cut outstanding options by about 3.44 million shares. BNY Mellon reduced its MRNA stake by 16% last quarter, while Campbell & CO opened a new position. MRNA shares are trading higher intraday as investors await the vote and assess recent earnings.
12 November 2025
·
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Moderna shares rose mid-session Tuesday after UBS cited 2026 upside tied to cost cuts and pipeline progress. Redburn Atlantic lowered its price target to $36, while Bernstein reiterated a $25 target and neutral view, highlighting the need for further expense reductions. The moves follow last week’s Q3 report, which showed a narrower loss and tighter 2025 guidance.
11 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

U.S. stocks opened lower Thursday as investors weighed weak private jobs data and mixed earnings. Challenger reported over 150,000 announced layoffs in October, the highest for the month in more than 20 years. The dollar fell for a second day as traders raised odds of a December Fed rate cut. Qualcomm and DoorDash dropped on company risks; Datadog and Moderna gained on strong results.
6 November 2025
······
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna reported Q3 2025 revenue of $1.02 billion and a GAAP loss of $0.51 per share, both ahead of analyst forecasts, driven by $971 million in COVID-19 vaccine sales. The company narrowed its full-year revenue outlook to $1.6–$2.0 billion, cut operating-expense guidance by $700 million, and raised its year-end cash target. Shares rose pre-market but traded unevenly during the session.
6 November 2025
··
Nasdaq Rally Amid Tech Frenzy: Markets Brush Off Shutdown Fears in Late September 2025

U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus

U.S. equity futures edged lower early Thursday as Asian markets rebounded on strong U.S. data, while European shares slipped. Treasury yields rose and the dollar stayed firm. Key U.S. data releases include jobless claims and productivity at 8:30 a.m. ET. Qualcomm, Arm, and Snap moved pre-market on earnings, with several major reports due before and after the bell.
6 November 2025
········
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna shares surged 12% to near $27.50 on Oct. 30, 2025, after reports of takeover talks with a large drugmaker. The rally follows a STAT News report on possible deals, but Moderna declined comment. Despite gains, the stock remains down about 37% year-to-date. Recent FDA approvals include updated COVID and RSV vaccines, but falling COVID demand has cut 2025 revenue and forced cost reductions.
30 October 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 19.10.2025

China blocked Ant Group and JD.com from launching stablecoins, reinforcing state control over digital currency. U.S. stock futures rose ahead of a packed earnings week, with Tesla and Netflix among companies reporting. IonQ reported Q3 revenue up 102% to $12.4 million but posted a $52.5 million net loss, while Nvidia posted record Q3 revenue of $35.1 billion.
19 October 2025
···········
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna shares rose 5% to $28 but remain down 35% in 2024 and nearly 80% below last year’s level. COVID vaccine sales have collapsed from $18.9 billion in 2022 to $3.1 billion, and Q2 revenue fell 41% to $142 million. The company cut its 2025 revenue forecast and is laying off 10% of staff. Early data from an experimental cancer vaccine showed a 24% tumor response rate in advanced melanoma.
16 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna closed at $27.34 on Oct 7, 2025, with a market cap near $11 billion. Q2 revenue fell 41% year-over-year to $142 million, and the company posted a net loss of $0.8 billion. U.S. and EU regulators limited updated COVID booster use, narrowing near-term revenue prospects. Analysts’ 12-month price targets remain high, but sales forecasts have repeatedly missed expectations.
8 October 2025
··
1 2 3 4

Stock Market Today

  • Soybeans Close Slightly Lower as Traders Reduce Long Positions Ahead of June Acreage Report
    June 28, 2026, 10:43 PM EDT. Soybeans ended Friday's session with minor losses, as July contracts expired and traders adjusted positions ahead of Tuesday's June Acreage report from USDA's National Agricultural Statistics Service (NASS). Speculators trimmed net long soybean positions by 16,139 contracts, mainly through exiting long positions. Cash bean prices declined 2.5 cents to $10.76 per bushel. Soymeal futures fell 40 cents, while soy oil front-month futures gained up to 49 points. Export sales remain strong, with old crop commitments matching USDA projections and new crop sales significantly higher than last year. Market watchers await NASS's report, which is expected to confirm 85.2 million acres planted this spring, potentially impacting prices and trade flows.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop